Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 287

1.

Future epidemiological and economic impacts of universal influenza vaccines.

Sah P, Alfaro-Murillo JA, Fitzpatrick MC, Neuzil KM, Meyers LA, Singer BH, Galvani AP.

Proc Natl Acad Sci U S A. 2019 Oct 8;116(41):20786-20792. doi: 10.1073/pnas.1909613116. Epub 2019 Sep 23.

2.

Modelling microbial infection to address global health challenges.

Fitzpatrick MC, Bauch CT, Townsend JP, Galvani AP.

Nat Microbiol. 2019 Oct;4(10):1612-1619. doi: 10.1038/s41564-019-0565-8. Epub 2019 Sep 20. Review.

PMID:
31541212
3.

Impact of One-Health framework on vaccination cost-effectiveness: A case study of rabies in Ethiopia.

Beyene TJ, Fitzpatrick MC, Galvani AP, Mourits MCM, Revie CW, Cernicchiaro N, Sanderson MW, Hogeveen H.

One Health. 2019 Aug 21;8:100103. doi: 10.1016/j.onehlt.2019.100103. eCollection 2019 Dec.

4.

The global burden of HIV and prospects for control.

Pandey A, Galvani AP.

Lancet HIV. 2019 Aug 19. pii: S2352-3018(19)30230-9. doi: 10.1016/S2352-3018(19)30230-9. [Epub ahead of print] No abstract available.

5.

Correction to Discovery of Entrectinib: A New 3-Aminoindazole as a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.

Menichincheri M, Ardini E, Magnaghi P, Avanzi N, Banfi P, Bossi R, Buffa L, Canevari G, Ceriani L, Colombo M, Corti L, Donati D, Fasolini M, Felder E, Fiorelli C, Fiorentini F, Galvani A, Isacchi A, Borgia AL, Marchionni C, Nesi M, Orrenius C, Panzeri A, Pesenti E, Rusconi L, Saccardo MB, Vanotti E, Perrone E, Orsini P.

J Med Chem. 2019 Sep 12;62(17):8364. doi: 10.1021/acs.jmedchem.9b01259. Epub 2019 Aug 19. No abstract available.

PMID:
31424209
6.

Quantifying risk factors to guide progress towards leprosy elimination.

Pandey A, Galvani AP.

Lancet Glob Health. 2019 Sep;7(9):e1154-e1155. doi: 10.1016/S2214-109X(19)30330-4. Epub 2019 Jul 19. No abstract available.

7.

Implementation of Syringe Services Programs to Prevent Rapid Human Immunodeficiency Virus Transmission in Rural Counties in the United States: A Modeling Study.

Goedel WC, King MRF, Lurie MN, Galea S, Townsend JP, Galvani AP, Friedman SR, Marshall BDL.

Clin Infect Dis. 2019 May 30. pii: ciz321. doi: 10.1093/cid/ciz321. [Epub ahead of print]

PMID:
31143944
8.

Ebola vaccination in the Democratic Republic of the Congo.

Wells CR, Pandey A, Parpia AS, Fitzpatrick MC, Meyers LA, Singer BH, Galvani AP.

Proc Natl Acad Sci U S A. 2019 May 14;116(20):10178-10183. doi: 10.1073/pnas.1817329116. Epub 2019 Apr 29.

PMID:
31036657
9.

Discovery of Stereospecific PARP-1 Inhibitor Isoindolinone NMS-P515.

Papeo G, Orsini P, Avanzi NR, Borghi D, Casale E, Ciomei M, Cirla A, Desperati V, Donati D, Felder ER, Galvani A, Guanci M, Isacchi A, Posteri H, Rainoldi S, Riccardi-Sirtori F, Scolaro A, Montagnoli A.

ACS Med Chem Lett. 2019 Mar 13;10(4):534-538. doi: 10.1021/acsmedchemlett.8b00569. eCollection 2019 Apr 11.

PMID:
30996792
10.

Metrics and benchmarks for HIV transition - Authors' reply.

Pandey A, Fitzpatrick MC, Galvani AP.

Lancet HIV. 2019 Mar;6(3):e150. doi: 10.1016/S2352-3018(19)30049-9. No abstract available.

PMID:
30846055
11.

Harnessing synergies at the interface of public health and the security sector.

Thomson N, Littlejohn M, Strathdee SA, Southby RF, Coghlan B, Rosenfeld JV, Galvani AP.

Lancet. 2019 Jan 19;393(10168):207-209. doi: 10.1016/S0140-6736(18)32999-4. No abstract available.

PMID:
30663581
12.

Resolving the apparent transmission paradox of African sleeping sickness.

Capewell P, Atkins K, Weir W, Jamonneau V, Camara M, Clucas C, Swar NK, Ngoyi DM, Rotureau B, Garside P, Galvani AP, Bucheton B, MacLeod A.

PLoS Biol. 2019 Jan 11;17(1):e3000105. doi: 10.1371/journal.pbio.3000105. eCollection 2019 Jan.

13.

Real-time PCR detection of Toxoplasma gondii in surface water samples in São Paulo, Brazil.

Galvani AT, Christ APG, Padula JA, Barbosa MRF, de Araújo RS, Sato MIZ, Razzolini MTP.

Parasitol Res. 2019 Feb;118(2):631-640. doi: 10.1007/s00436-018-6185-z. Epub 2019 Jan 4.

PMID:
30607608
14.

What Is the Value of Different Zika Vaccination Strategies to Prevent and Mitigate Zika Outbreaks?

Bartsch SM, Asti L, Cox SN, Durham DP, Randall S, Hotez PJ, Galvani AP, Lee BY.

J Infect Dis. 2019 Aug 9;220(6):920-931. doi: 10.1093/infdis/jiy688.

PMID:
30544164
15.

The economic value of identifying and treating Chagas disease patients earlier and the impact on Trypanosoma cruzi transmission.

Bartsch SM, Avelis CM, Asti L, Hertenstein DL, Ndeffo-Mbah M, Galvani A, Lee BY.

PLoS Negl Trop Dis. 2018 Nov 5;12(11):e0006809. doi: 10.1371/journal.pntd.0006809. eCollection 2018 Nov.

16.

Defining control of HIV epidemics.

Galvani AP, Pandey A, Fitzpatrick MC, Medlock J, Gray GE.

Lancet HIV. 2018 Nov;5(11):e667-e670. doi: 10.1016/S2352-3018(18)30178-4. Epub 2018 Oct 9.

PMID:
30314745
17.

Potential effectiveness of long-acting injectable pre-exposure prophylaxis for HIV prevention in men who have sex with men: a modelling study.

Marshall BDL, Goedel WC, King MRF, Singleton A, Durham DP, Chan PA, Townsend JP, Galvani AP.

Lancet HIV. 2018 Sep;5(9):e498-e505. doi: 10.1016/S2352-3018(18)30097-3. Epub 2018 Jun 13.

18.

Policy Lessons From Quantitative Modeling of Leprosy.

Medley GF, Blok DJ, Crump RE, Hollingsworth TD, Galvani AP, Ndeffo-Mbah ML, Porco TC, Richardus JH.

Clin Infect Dis. 2018 Jun 1;66(suppl_4):S281-S285. doi: 10.1093/cid/ciy005.

19.

Assessing Strategies Against Gambiense Sleeping Sickness Through Mathematical Modeling.

Rock KS, Ndeffo-Mbah ML, Castaño S, Palmer C, Pandey A, Atkins KE, Ndung'u JM, Hollingsworth TD, Galvani A, Bever C, Chitnis N, Keeling MJ.

Clin Infect Dis. 2018 Jun 1;66(suppl_4):S286-S292. doi: 10.1093/cid/ciy018.

20.

The Challenge of Vanquishing HIV for the Next Generation-Facing the Future.

Fitzpatrick MC, Gray GE, Galvani AP.

JAMA Pediatr. 2018 Jul 1;172(7):609-610. doi: 10.1001/jamapediatrics.2018.0389. No abstract available.

PMID:
29800028
21.

Optimizing the impact of low-efficacy influenza vaccines.

Sah P, Medlock J, Fitzpatrick MC, Singer BH, Galvani AP.

Proc Natl Acad Sci U S A. 2018 May 15;115(20):5151-5156. doi: 10.1073/pnas.1802479115. Epub 2018 Apr 30.

22.

Evaluating Vaccination Strategies for Zika Virus in the Americas.

Durham DP, Fitzpatrick MC, Ndeffo-Mbah ML, Parpia AS, Michael NL, Galvani AP.

Ann Intern Med. 2018 May 1;168(9):621-630. doi: 10.7326/M17-0641. Epub 2018 Apr 3.

23.

Spatial distribution of leprosy in India: an ecological study.

Grantz KH, Chabaari W, Samuel RK, Gershom B, Blum L, Worden L, Ackley S, Liu F, Lietman TM, Galvani AP, Prajna L, Porco TC.

Infect Dis Poverty. 2018 Mar 27;7(1):20. doi: 10.1186/s40249-018-0402-y.

24.

Dynamic Models of Infectious Disease Transmission in Prisons and the General Population.

Ndeffo-Mbah ML, Vigliotti VS, Skrip LA, Dolan K, Galvani AP.

Epidemiol Rev. 2018 Jun 1;40(1):40-57. doi: 10.1093/epirev/mxx014.

25.

Detection and molecular characterization of Cryptosporidium species and Giardia assemblages in two watersheds in the metropolitan region of São Paulo, Brazil.

de Araújo RS, Aguiar B, Dropa M, Razzolini MTP, Sato MIZ, de Souza Lauretto M, Galvani AT, Padula JA, Matté GR, Matté MH.

Environ Sci Pollut Res Int. 2018 May;25(15):15191-15203. doi: 10.1007/s11356-018-1620-3. Epub 2018 Mar 20.

PMID:
29560592
26.

Are the London Declaration's 2020 goals sufficient to control Chagas disease?: Modeling scenarios for the Yucatan Peninsula.

Lee BY, Bartsch SM, Skrip L, Hertenstein DL, Avelis CM, Ndeffo-Mbah M, Tilchin C, Dumonteil EO, Galvani A.

PLoS Negl Trop Dis. 2018 Mar 19;12(3):e0006337. doi: 10.1371/journal.pntd.0006337. eCollection 2018 Mar.

27.

Underestimation of the global burden of schistosomiasis.

King CH, Galvani AP.

Lancet. 2018 Jan 27;391(10118):307-308. doi: 10.1016/S0140-6736(18)30098-9. Epub 2018 Jan 31. No abstract available.

PMID:
29413041
28.

Afatinib Is a New Therapeutic Approach in Chordoma with a Unique Ability to Target EGFR and Brachyury.

Magnaghi P, Salom B, Cozzi L, Amboldi N, Ballinari D, Tamborini E, Gasparri F, Montagnoli A, Raddrizzani L, Somaschini A, Bosotti R, Orrenius C, Bozzi F, Pilotti S, Galvani A, Sommer J, Stacchiotti S, Isacchi A.

Mol Cancer Ther. 2018 Mar;17(3):603-613. doi: 10.1158/1535-7163.MCT-17-0324. Epub 2017 Dec 13.

29.

HIV criminalization exacerbates subpar diagnosis and treatment across the United States: response to the 'Association of HIV diagnosis rates and laws criminalizing HIV exposure in the United States'.

Sah P, Fitzpatrick MC, Pandey A, Galvani AP.

AIDS. 2017 Nov 13;31(17):2437-2439. doi: 10.1097/QAD.0000000000001636. No abstract available.

30.

California Universal Health Care Bill: an economic stimulus and life-saving proposal.

Galvani AP, Durham DP, Vermund SH, Fitzpatrick MC.

Lancet. 2017 Oct 28;390(10106):2012-2014. doi: 10.1016/S0140-6736(17)32148-7. Epub 2017 Sep 17. No abstract available.

31.

Establishment and genomic characterization of the new chordoma cell line Chor-IN-1.

Bosotti R, Magnaghi P, Di Bella S, Cozzi L, Cusi C, Bozzi F, Beltrami N, Carapezza G, Ballinari D, Amboldi N, Lupi R, Somaschini A, Raddrizzani L, Salom B, Galvani A, Stacchiotti S, Tamborini E, Isacchi A.

Sci Rep. 2017 Aug 23;7(1):9226. doi: 10.1038/s41598-017-10044-3.

32.

Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors.

Weiss GJ, Jameson G, Von Hoff DD, Valsasina B, Davite C, Di Giulio C, Fiorentini F, Alzani R, Carpinelli P, Di Sanzo A, Galvani A, Isacchi A, Ramanathan RK.

Invest New Drugs. 2018 Feb;36(1):85-95. doi: 10.1007/s10637-017-0491-7. Epub 2017 Jul 20.

PMID:
28726132
33.

Saving lives efficiently across sectors: the need for a Congressional cost-effectiveness committee.

Fitzpatrick MC, Singer BH, Hotez PJ, Galvani AP.

Lancet. 2017 Nov 25;390(10110):2410-2412. doi: 10.1016/S0140-6736(17)31440-X. Epub 2017 Jun 29. Review. No abstract available.

34.

Histones H3 and H4 require their relevant amino-tails for efficient nuclear import and replication-coupled chromatin assembly in vivo.

Ejlassi A, Menil-Philippot V, Galvani A, Thiriet C.

Sci Rep. 2017 Jun 8;7(1):3050. doi: 10.1038/s41598-017-03218-6.

35.

Fund global health: Save lives and money.

Galvani AP, Fitzpatrick MC, Vermund SH, Singer BH.

Science. 2017 Jun 9;356(6342):1018-1019. doi: 10.1126/science.aan4683. No abstract available.

36.

Assessing real-time Zika risk in the United States.

Castro LA, Fox SJ, Chen X, Liu K, Bellan SE, Dimitrov NB, Galvani AP, Meyers LA.

BMC Infect Dis. 2017 May 4;17(1):284. doi: 10.1186/s12879-017-2394-9.

37.

The potential economic burden of Zika in the continental United States.

Lee BY, Alfaro-Murillo JA, Parpia AS, Asti L, Wedlock PT, Hotez PJ, Galvani AP.

PLoS Negl Trop Dis. 2017 Apr 27;11(4):e0005531. doi: 10.1371/journal.pntd.0005531. eCollection 2017 Apr.

38.

Quantitative assessment of the impact of partially protective anti-schistosomiasis vaccines.

Alsallaq RA, Gurarie D, Ndeffo Mbah M, Galvani A, King C.

PLoS Negl Trop Dis. 2017 Apr 14;11(4):e0005544. doi: 10.1371/journal.pntd.0005544. eCollection 2017 Apr.

39.

Modelling the impact of antimalarial quality on the transmission of sulfadoxine-pyrimethamine resistance in Plasmodium falciparum.

Brock AR, Ross JV, Greenhalgh S, Durham DP, Galvani A, Parikh S, Esterman A.

Infect Dis Model. 2017 Apr 15;2(2):161-187. doi: 10.1016/j.idm.2017.04.001. eCollection 2017 May.

40.

Characterizing risk of Ebola transmission based on frequency and type of case-contact exposures.

Skrip LA, Fallah MP, Gaffney SG, Yaari R, Yamin D, Huppert A, Bawo L, Nyenswah T, Galvani AP.

Philos Trans R Soc Lond B Biol Sci. 2017 May 26;372(1721). pii: 20160301. doi: 10.1098/rstb.2016.0301.

41.

Effectiveness of UNAIDS targets and HIV vaccination across 127 countries.

Medlock J, Pandey A, Parpia AS, Tang A, Skrip LA, Galvani AP.

Proc Natl Acad Sci U S A. 2017 Apr 11;114(15):4017-4022. doi: 10.1073/pnas.1620788114. Epub 2017 Mar 20.

42.

Forecasting the new case detection rate of leprosy in four states of Brazil: A comparison of modelling approaches.

Blok DJ, Crump RE, Sundaresh R, Ndeffo-Mbah M, Galvani AP, Porco TC, de Vlas SJ, Medley GF, Richardus JH.

Epidemics. 2017 Mar;18:92-100. doi: 10.1016/j.epidem.2017.01.005.

43.

Comparison and validation of two computational models of Chagas disease: A thirty year perspective from Venezuela.

Bartsch SM, Peterson JK, Hertenstein DL, Skrip L, Ndeffo-Mbah M, Galvani AP, Dobson AP, Lee BY.

Epidemics. 2017 Mar;18:81-91. doi: 10.1016/j.epidem.2017.02.004.

44.

Data-driven models to predict the elimination of sleeping sickness in former Equateur province of DRC.

Rock KS, Pandey A, Ndeffo-Mbah ML, Atkins KE, Lumbala C, Galvani A, Keeling MJ.

Epidemics. 2017 Mar;18:101-112. doi: 10.1016/j.epidem.2017.01.006.

45.

Bolstering Community Cooperation in Ebola Resurgence Protocols: Combining Field Blood Draw and Point-of-Care Diagnosis.

Fallah MP, Skrip LA, Raftery P, Kullie M, Borbor W, Laney AS, Blackley DJ, Christie A, Dokubo EK, Lo TQ, Coulter S, Baller A, Vonhm BT, Bemah P, Lomax S, Yeiah A, Wapoe-Sackie Y, Mann J, Clement P, Davies-Wayne G, Hamblion E, Wolfe C, Williams D, Gasasira A, Kateh F, Nyenswah TG, Galvani AP.

PLoS Med. 2017 Jan 24;14(1):e1002227. doi: 10.1371/journal.pmed.1002227. eCollection 2017 Jan.

46.

Global elimination of lymphatic filariasis.

Ndeffo-Mbah ML, Galvani AP.

Lancet Infect Dis. 2017 Apr;17(4):358-359. doi: 10.1016/S1473-3099(16)30544-8. Epub 2016 Dec 22. No abstract available.

47.

One Health approach to cost-effective rabies control in India.

Fitzpatrick MC, Shah HA, Pandey A, Bilinski AM, Kakkar M, Clark AD, Townsend JP, Abbas SS, Galvani AP.

Proc Natl Acad Sci U S A. 2016 Dec 20;113(51):14574-14581. doi: 10.1073/pnas.1604975113.

48.

Philippine drug war and impending public health crisis.

Macarayan E, Ndeffo-Mbah M, Beyrer C, Galvani AP.

Lancet. 2016 Dec 10;388(10062):2870. doi: 10.1016/S0140-6736(16)32468-0. No abstract available.

PMID:
27979404
49.

Human-environment interactions in population and ecosystem health.

Galvani AP, Bauch CT, Anand M, Singer BH, Levin SA.

Proc Natl Acad Sci U S A. 2016 Dec 20;113(51):14502-14506. doi: 10.1073/pnas.1618138113. Epub 2016 Dec 12. No abstract available.

50.

Cost-Effectiveness of Community-Based TB/HIV Screening and Linkage to Care in Rural South Africa.

Gilbert JA, Shenoi SV, Moll AP, Friedland GH, Paltiel AD, Galvani AP.

PLoS One. 2016 Dec 1;11(12):e0165614. doi: 10.1371/journal.pone.0165614. eCollection 2016.

Supplemental Content

Loading ...
Support Center